Focus on Prostate Cancer
by Anne Katz, RN, PhD
So you’ve been with this same man for 10 or 20 or even 50 years and you each know how the other thinks, right? Perhaps at times you even say the exact same thing at the exact same time and you both laugh at how well you know each other. But when illness occurs, those automatic and familiar ways of communicating often don’t work any longer or as effectively. Times of crisis require great communication, not just good communication; these times require the use of words rather than looks or telepathy.
by Alan M. Nieder, MD, and Rafael Yanes, MD
Prostate cancer is the most common non-skin-related cancer for American men. The American Cancer Society estimates that nearly 240,000 men will be diagnosed with prostate cancer this year. While prostate cancer can be aggressive, most men are diagnosed at an early and curable stage. Additionally, most newly diagnosed men have no signs or symptoms of prostate cancer and feel perfectly well. They are typically only diagnosed because they have had a PSA blood test that prompted a prostate biopsy.
The U.S. Food and Drug Administration has approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.